Opsin Receptors in Melasma

Universidad Autonoma de San Luis Potosí

Status: Completed

Conditions: Melasma

Treatments: Drug: Retinoic acid

Study type: Interventional

Funder types: Other

Identifiers

NCT04417348

OPN3Mel

Details and patient eligibility

About

Melasma is a hyperpigmentation disorder that is probably exacerbated by visible light. Opsin receptors (OPN 1, 2, 3, 4 y 5) were described in the skin, being capable of activating melanogenesis induced by visible light. The aim of this study was to evaluate the expression of OPN in melasma skin and its changes following treatment with UV-Vis filter and 0.05% retinoic acid for 12 weeks.

Enrollment: 15 patients

Sex: Female

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients diagnosed with melasma, of 18 years of age and older, without previous treatment or photoprotection measures within the previous 4 weeks, who had Melasma Activity and Severity Index (MASI) scores higher than 7

Exclusion criteria

• pregnancy or nursing, menopause, coexistence of other pigmentation conditions, heat exposure, regular exercise, diet restriction, consumption of food supplements or any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months, and women who had given birth within 1 year

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups, including a placebo group

Retinoic Acid

Active Comparator group

Description:

patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter

Treatment:

Drug: Retinoic acid

Sunscreen

Placebo Comparator group

Description:

patients with melasma treated with UV-Visible light filter alone

Treatment:

Drug: Retinoic acid